2. Reginster JY, Beaudart C, Buckinx F, Bruyere O. Osteoporosis and sarcopenia: two diseases or one? Curr Opin Clin Nutr Metab Care 2016;19:31-6.
7. Fatima M, Brennan-Olsen SL, Duque G. Therapeutic approaches to osteosarcopenia: insights for the clinician. Ther Adv Musculoskelet Dis 2019;11:1759720X19867009.
8. Hannan MT, Tucker KL, Dawson-Hughes B, Cupples LA, Felson DT, Kiel DP. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000;15:2504-12.
14. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012;66:1139-46.
15. Kirk B, Miller S, Zanker J, Duque G. A clinical guide to the pathophysiology, diagnosis and treatment of osteosarcopenia. Maturitas 2020;140:27-33.
18. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
29. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-41.
31. Cadena M. Postmenopausal women with osteoporosis, comparing treatment of oral bisphosphonates to denosumab [dissertation]. Stockton, CA: University of the Pacific; 2019.
33. Augoulea A, Tsakonas E, Triantafyllopoulos I, Rizos D, Armeni E, Tsoltos N, et al. Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women. J Musculoskelet Neuronal Interact 2017;17:444-9.
36. Suzuki T, Yoshida H, Kim H, Yukawa H, Sugiura M, Furuna T, et al. Walking speed as a good predictor for maintenance of I‐ADL among the rural community elderly in Japan: a 5‐year follow‐up study from TMIG‐LISA. Geriatr Gerontol Int 2003;3:S6-14.
38. Kwon J, Suzuki T, Yoshida H, Kim H, Yoshida Y, Iwasa H, et al. Association between change in bone mineral density and decline in usual walking speed in elderly community-dwelling Japanese women during 2 years of follow-up. J Am Geriatr Soc 2007;55:240-4.
39. Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol 2018;179:R31-45.
40. Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 2008;23:672-82.
41. Dufresne SS, Boulanger-Piette A, Bosse S, Frenette J. Physiological role of receptor activator nuclear factor-kB (RANK) in denervation-induced muscle atrophy and dysfunction. Receptors Clin Investig 2016;3:e13231-6.
44. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531-7.